View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsHLB SCIENCE 将来の成長Future 基準チェック /06現在、 HLB SCIENCEの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長19.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Sep 18HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire HLB SCIENCE Inc. (XKON:A343090) from HLB GLOBAL Co., Ltd. (KOSE:A003580), HLB bioStep Co.,Ltd. (KOSDAQ:A278650), HLB Life Science Co., Ltd. (KOSDAQ:A067630), Yoon Jong-seon and others for KRW 30.9 billion.HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire HLB SCIENCE Inc. (XKON:A343090) from HLB GLOBAL Co., Ltd. (KOSE:A003580), HLB bioStep Co.,Ltd. (KOSDAQ:A278650), HLB Life Science Co., Ltd. (KOSDAQ:A067630), Yoon Jong-seon and others for KRW 30.9 billion on September 17, 2025. HLB Co., Ltd and HLB SCIENCE Inc will enter into an agreement on September 17, 2025. HLB Co., Ltd. entered into merger agreement to acquire HLB SCIENCE Inc. from HLB GLOBAL Co., Ltd., HLB bioStep Co.,Ltd., HLB Life Science Co., Ltd., Yoon Jong-seon and others on September 18, 2025. The consideration consists of 0.8 million common equity of HLB Co., Ltd. at a ratio of 0.044632 per common equity of HLB SCIENCE Inc. As part of consideration, an undisclosed value is paid towards common equity of HLB SCIENCE Inc. After the completion of this merger, Jin Yang-gon's stake in HLB Co., Ltd., is expected to change from 7.22% to 7.18%. The approvals of board of directors and general shareholders' meeting of HLB Co., Ltd. and HLB SCIENCE Inc., all requirements required under relevant laws and regulations of the Republic of Korea. The transaction is expected to close on January 1, 2026.New Risk • Aug 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩30.8b market cap, or US$22.2m).New Risk • Jul 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$20.4m).お知らせ • Mar 07HLB SCIENCE Inc., Annual General Meeting, Mar 25, 2025HLB SCIENCE Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 66, achasan-ro, seongdong-gu, seoul South KoreaNew Risk • Mar 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩41.4b market cap, or US$31.7m).New Risk • Oct 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 50% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (₩28.6b market cap, or US$21.1m).お知らせ • Feb 02HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from KNOTUS Co.,LtdHLB SCIENCE Inc. announced a private placement of series 4 unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 2,000,000,000 on February 1, 2023. The transaction will include participation from KNOTUS Co.,Ltd. The bonds carry a coupon rate of 2% and yield to maturity rate of 2% and will mature on February 9, 2028. The series 4 bonds are fully convertible into 782,778 common shares at a conversion price of KRW 2,555 per share from February 9, 2024 to January 9, 2028. The bonds are restricted to a hold period of 1 year from the date of issuance. The transaction has been approved by shareholders of the company. The transaction is expected to close on February 9, 2023. On the same date, the company announced a private placement of 1,304,348 common shares at an issue price of KRW 2,300 per share for gross proceeds of KRW 3,000,000,400. The transaction will include participation from KNOTUS Co.,Ltd for 1,304,348 shares. The shares are restricted to a hold period of one year. The method of capital is through third party allocation increase. The transaction has been approved by shareholders of the company. The transaction is expected to close on February 9, 2023.お知らせ • Jun 16DandiBioscience, Inc. announced that it expects to receive KRW 8.4 billion in fundingDandiBioscience, Inc. (XKON:A343090) announced that it will issue round 3 non-guaranteed private equity convertible bonds with bearer food vouchers for gross proceeds of KRW 8,400,000,000 on June 15, 2021. The transaction will include participation from 21-07 Cyclamen New Technology Association No. 38-Eastgate Investment Co. , Ltd. for 2,000,000,000, Green Marine No. 1 Fund for 4,000,000,000, Jihoon Park for 2,000,000,000, Dong-ho Dong for 100,000,000, along with executives In-deok Jeong and Yong-joo Kim and Young-min Park for 50,000,000 each. The transaction will also include participation from Won-jin Kwon, Jin-wook Baek and Ji-won Kang for 50,000,000 each. The bonds will be issued at par. The bonds carry a coupon rate of 1% with a yield to maturity of 2% per annum. The bonds will mature on July 07, 2024. The bonds are convertible into 957,041 common shares of the company at a fixed conversion price of KRW 8,777 per share from July 07, 2022 to June 07, 2024. The date of subscription is June 17, 2021 and expected date of payment is July 07, 2021. The transaction is approved by the board of directors of the company. The bonds are subject to prohibition of conversion and division of rights for one year from the date of issue of bonds.お知らせ • Apr 24DandiBioscience, Inc. announced that it has received KRW 1.3 billion in fundingOn April 22, 2021, DandiBioscience, Inc. (XKON:A343090) closed the transaction.お知らせ • Mar 04DandiBioscience, Inc., Annual General Meeting, Mar 25, 2021DandiBioscience, Inc., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Feb 23New 90-day low: ₩4,900The company is down 24% from its price of ₩6,470 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Feb 04New 90-day low: ₩5,500The company is down 21% from its price of ₩6,980 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period.Is New 90 Day High Low • Jan 06New 90-day low: ₩6,100The company is down 2.0% from its price of ₩6,220 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period.Is New 90 Day High Low • Nov 02New 90-day high: ₩6,650The company is up 29% from its price of ₩5,150 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period.Is New 90 Day High Low • Oct 15New 90-day high: ₩6,440The company is up 20% from its price of ₩5,380 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、HLB SCIENCE は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XKON:A343090 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: A343090の予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A343090の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A343090の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A343090の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A343090の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A343090の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/05 07:45終値2025/12/26 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HLB SCIENCE Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 18HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire HLB SCIENCE Inc. (XKON:A343090) from HLB GLOBAL Co., Ltd. (KOSE:A003580), HLB bioStep Co.,Ltd. (KOSDAQ:A278650), HLB Life Science Co., Ltd. (KOSDAQ:A067630), Yoon Jong-seon and others for KRW 30.9 billion.HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire HLB SCIENCE Inc. (XKON:A343090) from HLB GLOBAL Co., Ltd. (KOSE:A003580), HLB bioStep Co.,Ltd. (KOSDAQ:A278650), HLB Life Science Co., Ltd. (KOSDAQ:A067630), Yoon Jong-seon and others for KRW 30.9 billion on September 17, 2025. HLB Co., Ltd and HLB SCIENCE Inc will enter into an agreement on September 17, 2025. HLB Co., Ltd. entered into merger agreement to acquire HLB SCIENCE Inc. from HLB GLOBAL Co., Ltd., HLB bioStep Co.,Ltd., HLB Life Science Co., Ltd., Yoon Jong-seon and others on September 18, 2025. The consideration consists of 0.8 million common equity of HLB Co., Ltd. at a ratio of 0.044632 per common equity of HLB SCIENCE Inc. As part of consideration, an undisclosed value is paid towards common equity of HLB SCIENCE Inc. After the completion of this merger, Jin Yang-gon's stake in HLB Co., Ltd., is expected to change from 7.22% to 7.18%. The approvals of board of directors and general shareholders' meeting of HLB Co., Ltd. and HLB SCIENCE Inc., all requirements required under relevant laws and regulations of the Republic of Korea. The transaction is expected to close on January 1, 2026.
New Risk • Aug 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩30.8b market cap, or US$22.2m).
New Risk • Jul 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$20.4m).
お知らせ • Mar 07HLB SCIENCE Inc., Annual General Meeting, Mar 25, 2025HLB SCIENCE Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 66, achasan-ro, seongdong-gu, seoul South Korea
New Risk • Mar 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩41.4b market cap, or US$31.7m).
New Risk • Oct 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 50% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (₩28.6b market cap, or US$21.1m).
お知らせ • Feb 02HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from KNOTUS Co.,LtdHLB SCIENCE Inc. announced a private placement of series 4 unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 2,000,000,000 on February 1, 2023. The transaction will include participation from KNOTUS Co.,Ltd. The bonds carry a coupon rate of 2% and yield to maturity rate of 2% and will mature on February 9, 2028. The series 4 bonds are fully convertible into 782,778 common shares at a conversion price of KRW 2,555 per share from February 9, 2024 to January 9, 2028. The bonds are restricted to a hold period of 1 year from the date of issuance. The transaction has been approved by shareholders of the company. The transaction is expected to close on February 9, 2023. On the same date, the company announced a private placement of 1,304,348 common shares at an issue price of KRW 2,300 per share for gross proceeds of KRW 3,000,000,400. The transaction will include participation from KNOTUS Co.,Ltd for 1,304,348 shares. The shares are restricted to a hold period of one year. The method of capital is through third party allocation increase. The transaction has been approved by shareholders of the company. The transaction is expected to close on February 9, 2023.
お知らせ • Jun 16DandiBioscience, Inc. announced that it expects to receive KRW 8.4 billion in fundingDandiBioscience, Inc. (XKON:A343090) announced that it will issue round 3 non-guaranteed private equity convertible bonds with bearer food vouchers for gross proceeds of KRW 8,400,000,000 on June 15, 2021. The transaction will include participation from 21-07 Cyclamen New Technology Association No. 38-Eastgate Investment Co. , Ltd. for 2,000,000,000, Green Marine No. 1 Fund for 4,000,000,000, Jihoon Park for 2,000,000,000, Dong-ho Dong for 100,000,000, along with executives In-deok Jeong and Yong-joo Kim and Young-min Park for 50,000,000 each. The transaction will also include participation from Won-jin Kwon, Jin-wook Baek and Ji-won Kang for 50,000,000 each. The bonds will be issued at par. The bonds carry a coupon rate of 1% with a yield to maturity of 2% per annum. The bonds will mature on July 07, 2024. The bonds are convertible into 957,041 common shares of the company at a fixed conversion price of KRW 8,777 per share from July 07, 2022 to June 07, 2024. The date of subscription is June 17, 2021 and expected date of payment is July 07, 2021. The transaction is approved by the board of directors of the company. The bonds are subject to prohibition of conversion and division of rights for one year from the date of issue of bonds.
お知らせ • Apr 24DandiBioscience, Inc. announced that it has received KRW 1.3 billion in fundingOn April 22, 2021, DandiBioscience, Inc. (XKON:A343090) closed the transaction.
お知らせ • Mar 04DandiBioscience, Inc., Annual General Meeting, Mar 25, 2021DandiBioscience, Inc., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Feb 23New 90-day low: ₩4,900The company is down 24% from its price of ₩6,470 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Feb 04New 90-day low: ₩5,500The company is down 21% from its price of ₩6,980 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period.
Is New 90 Day High Low • Jan 06New 90-day low: ₩6,100The company is down 2.0% from its price of ₩6,220 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period.
Is New 90 Day High Low • Nov 02New 90-day high: ₩6,650The company is up 29% from its price of ₩5,150 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period.
Is New 90 Day High Low • Oct 15New 90-day high: ₩6,440The company is up 20% from its price of ₩5,380 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 3.0% over the same period.